SCHEMBL10085576

SCHEMBL10085576

COCCn1c(=O)[nH]c2ccc(C)cc2c1=O

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 0.57
GAA P10253 8/20 0.57
HSD17B10 Q99714 7/20 0.57
KDM4E B2RXH2 6/20 0.57
GLA P06280 5/20 0.57
HPGD P15428 4/20 0.57
KMT2A Q03164 3/20 0.57
PKM P14618 2/20 0.57
HTT P42858 1/20 0.57
USP2 O75604 1/20 0.54
CASP1 P29466 1/20 0.54
CASP7 P55210 1/20 0.54
SMN1; SMN2 Q16637 2/20 0.50
TP53 P04637 1/20 0.47
NPC1 O15118 1/20 0.47
POLB P06746 1/20 0.47
RAB9A P51151 1/20 0.47
MAPK1 P28482 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10085587 0.86 HSD17B10 (0.45) ALDH1A1GAAHSD17B10KDM4EGLA
SCHEMBL25723962 0.85 ALDH1A1 (0.56) ALDH1A1GAAHSD17B10KDM4EGLA
SCHEMBL10084476 0.84 ADORA3 (0.49) ALDH1A1GAAHSD17B10KDM4EGLA
SCHEMBL10086066 0.83 ALDH1A1 (0.54) ALDH1A1GAAHSD17B10KDM4EGLA
SCHEMBL11014592 0.83 ALDH1A1 (0.47) ALDH1A1GAAKDM4EGLAHPGD
SCHEMBL8987676 0.83 POLB (0.47) ALDH1A1GAAHSD17B10KDM4EGLA
SCHEMBL8987717 0.82 POLB (0.51) ALDH1A1HSD17B10KDM4EHPGDPOLB
SCHEMBL22716785 0.81 CYP1A2 (0.65) ALDH1A1GAAHSD17B10KDM4EGLA
SCHEMBL31189218 0.81 CYP1A2 (0.65) ALDH1A1GAAHSD17B10KDM4EGLA
SCHEMBL434989 0.81 CYP1A2 (0.64) ALDH1A1GAAHSD17B10KDM4EGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590975-B1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2015-08-19 EP disclosed
US-8859544-B2 Indolizine derivatives, process for the preparation thereof and therapeutic use thereof SANOFI (FR) 2014-10-14 US disclosed
US-8859544-B2 Indolizine derivatives, process for the preparation thereof and therapeutic use thereof SANOFI (FR) 2014-10-14 US disclosed
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 US disclosed
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 US disclosed
WO-2012004731-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, INMT, IDO1 ALDH1A1 3536/4885GAA 3839/4885HSD17B10 4071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.